JP2017533223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533223A5 JP2017533223A5 JP2017523507A JP2017523507A JP2017533223A5 JP 2017533223 A5 JP2017533223 A5 JP 2017533223A5 JP 2017523507 A JP2017523507 A JP 2017523507A JP 2017523507 A JP2017523507 A JP 2017523507A JP 2017533223 A5 JP2017533223 A5 JP 2017533223A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- composition
- administered
- platin
- taxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072311P | 2014-10-29 | 2014-10-29 | |
| US62/072,311 | 2014-10-29 | ||
| PCT/US2015/057062 WO2016069392A1 (en) | 2014-10-29 | 2015-10-23 | Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533223A JP2017533223A (ja) | 2017-11-09 |
| JP2017533223A5 true JP2017533223A5 (enExample) | 2018-11-29 |
| JP6698648B2 JP6698648B2 (ja) | 2020-05-27 |
Family
ID=55858197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523507A Expired - Fee Related JP6698648B2 (ja) | 2014-10-29 | 2015-10-23 | ユビキチン活性化酵素阻害物質及び化学療法剤の投与 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20180133221A1 (enExample) |
| EP (1) | EP3212650B1 (enExample) |
| JP (1) | JP6698648B2 (enExample) |
| TW (1) | TW201625256A (enExample) |
| WO (1) | WO2016069392A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20120786T1 (hr) * | 2006-02-02 | 2012-11-30 | Millennium Pharmaceuticals, Inc. | Inhibitori aktivirajuä†eg enzima e1 |
| US8008307B2 (en) * | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| UA116534C2 (uk) * | 2012-02-17 | 2018-04-10 | Мілленніум Фармасьютікалз, Інк. | Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту |
-
2015
- 2015-10-23 US US15/522,715 patent/US20180133221A1/en not_active Abandoned
- 2015-10-23 WO PCT/US2015/057062 patent/WO2016069392A1/en not_active Ceased
- 2015-10-23 TW TW104135008A patent/TW201625256A/zh unknown
- 2015-10-23 JP JP2017523507A patent/JP6698648B2/ja not_active Expired - Fee Related
- 2015-10-23 EP EP15853752.2A patent/EP3212650B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533221A5 (enExample) | ||
| Postiglione et al. | Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategies | |
| Helm et al. | Enhancing the efficacy of cisplatin in ovarian cancer treatment–could arsenic have a role | |
| FI4403228T3 (fi) | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote | |
| JP2023541432A5 (enExample) | ||
| JP2015533176A5 (enExample) | ||
| JP2009514881A5 (enExample) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2014512356A5 (enExample) | ||
| JP2006504723A5 (enExample) | ||
| JP2012520323A5 (enExample) | ||
| JP2005511597A5 (enExample) | ||
| HRP20110245T1 (hr) | Derivati pirazolopirimidina kao inhibitori o ciklinu ovisne kinaze | |
| WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
| RU2013102398A (ru) | Лечение рака крови | |
| RU2013148732A (ru) | Комбинации соединений, ингибирующих акт, и химиотерапевтических агентов и способы их применения | |
| JP2013523656A5 (enExample) | ||
| JP2010522194A5 (enExample) | ||
| JP2016520528A5 (enExample) | ||
| NZ630392A (en) | Methods of treating lung cancer | |
| JP2017514800A5 (enExample) | ||
| Misiukiewicz et al. | Taxanes in cancer of the head and neck | |
| JP2019506392A5 (enExample) | ||
| JP2015514756A5 (enExample) | ||
| JP2022527334A5 (enExample) |